|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FHL1 |
Gene summary for FHL1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FHL1 | Gene ID | 2273 |
| Gene name | four and a half LIM domains 1 | |
| Gene Alias | FCMSU | |
| Cytomap | Xq26.3 | |
| Gene Type | protein-coding | GO ID | GO:0000082 | UniProtAcc | Q13642 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 2273 | FHL1 | P2T-E | Human | Esophagus | ESCC | 1.28e-13 | 3.02e-01 | 0.1177 |
| 2273 | FHL1 | P8T-E | Human | Esophagus | ESCC | 2.19e-02 | 2.64e-01 | 0.0889 |
| 2273 | FHL1 | P9T-E | Human | Esophagus | ESCC | 6.53e-09 | 5.36e-01 | 0.1131 |
| 2273 | FHL1 | P10T-E | Human | Esophagus | ESCC | 3.47e-13 | 2.78e-01 | 0.116 |
| 2273 | FHL1 | P11T-E | Human | Esophagus | ESCC | 2.59e-11 | 6.00e-01 | 0.1426 |
| 2273 | FHL1 | P12T-E | Human | Esophagus | ESCC | 6.89e-03 | 2.32e-01 | 0.1122 |
| 2273 | FHL1 | P16T-E | Human | Esophagus | ESCC | 4.53e-05 | -4.44e-02 | 0.1153 |
| 2273 | FHL1 | P19T-E | Human | Esophagus | ESCC | 7.74e-08 | 1.13e+00 | 0.1662 |
| 2273 | FHL1 | P21T-E | Human | Esophagus | ESCC | 2.62e-44 | 1.11e+00 | 0.1617 |
| 2273 | FHL1 | P22T-E | Human | Esophagus | ESCC | 6.33e-19 | 3.00e-01 | 0.1236 |
| 2273 | FHL1 | P26T-E | Human | Esophagus | ESCC | 8.90e-68 | 1.36e+00 | 0.1276 |
| 2273 | FHL1 | P28T-E | Human | Esophagus | ESCC | 1.70e-02 | -5.15e-02 | 0.1149 |
| 2273 | FHL1 | P31T-E | Human | Esophagus | ESCC | 1.88e-11 | 3.70e-01 | 0.1251 |
| 2273 | FHL1 | P32T-E | Human | Esophagus | ESCC | 6.17e-05 | 1.39e-01 | 0.1666 |
| 2273 | FHL1 | P38T-E | Human | Esophagus | ESCC | 2.45e-04 | 4.87e-01 | 0.127 |
| 2273 | FHL1 | P49T-E | Human | Esophagus | ESCC | 8.72e-21 | 2.24e+00 | 0.1768 |
| 2273 | FHL1 | P52T-E | Human | Esophagus | ESCC | 1.06e-14 | 9.92e-01 | 0.1555 |
| 2273 | FHL1 | P61T-E | Human | Esophagus | ESCC | 1.42e-07 | 2.19e-01 | 0.099 |
| 2273 | FHL1 | P79T-E | Human | Esophagus | ESCC | 8.45e-24 | 8.51e-01 | 0.1154 |
| 2273 | FHL1 | P80T-E | Human | Esophagus | ESCC | 3.89e-15 | 5.34e-01 | 0.155 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:004477216 | Esophagus | ESCC | mitotic cell cycle phase transition | 281/8552 | 424/18723 | 4.63e-18 | 4.45e-16 | 281 |
| GO:000734615 | Esophagus | ESCC | regulation of mitotic cell cycle | 293/8552 | 457/18723 | 8.00e-16 | 5.64e-14 | 293 |
| GO:190198713 | Esophagus | ESCC | regulation of cell cycle phase transition | 242/8552 | 390/18723 | 3.86e-11 | 1.26e-09 | 242 |
| GO:0016049110 | Esophagus | ESCC | cell growth | 289/8552 | 482/18723 | 1.29e-10 | 3.77e-09 | 289 |
| GO:190199013 | Esophagus | ESCC | regulation of mitotic cell cycle phase transition | 191/8552 | 299/18723 | 1.35e-10 | 3.94e-09 | 191 |
| GO:00457865 | Esophagus | ESCC | negative regulation of cell cycle | 236/8552 | 385/18723 | 3.62e-10 | 9.93e-09 | 236 |
| GO:000155819 | Esophagus | ESCC | regulation of cell growth | 248/8552 | 414/18723 | 2.97e-09 | 6.45e-08 | 248 |
| GO:00448394 | Esophagus | ESCC | cell cycle G2/M phase transition | 103/8552 | 148/18723 | 3.09e-09 | 6.67e-08 | 103 |
| GO:00000864 | Esophagus | ESCC | G2/M transition of mitotic cell cycle | 96/8552 | 137/18723 | 6.00e-09 | 1.23e-07 | 96 |
| GO:00109484 | Esophagus | ESCC | negative regulation of cell cycle process | 177/8552 | 294/18723 | 3.26e-07 | 4.59e-06 | 177 |
| GO:000008214 | Esophagus | ESCC | G1/S transition of mitotic cell cycle | 134/8552 | 214/18723 | 4.04e-07 | 5.55e-06 | 134 |
| GO:004484314 | Esophagus | ESCC | cell cycle G1/S phase transition | 148/8552 | 241/18723 | 5.68e-07 | 7.48e-06 | 148 |
| GO:19019883 | Esophagus | ESCC | negative regulation of cell cycle phase transition | 151/8552 | 249/18723 | 1.28e-06 | 1.57e-05 | 151 |
| GO:004593013 | Esophagus | ESCC | negative regulation of mitotic cell cycle | 143/8552 | 235/18723 | 1.84e-06 | 2.15e-05 | 143 |
| GO:190199113 | Esophagus | ESCC | negative regulation of mitotic cell cycle phase transition | 112/8552 | 179/18723 | 3.69e-06 | 4.03e-05 | 112 |
| GO:00459267 | Esophagus | ESCC | negative regulation of growth | 148/8552 | 249/18723 | 7.88e-06 | 7.73e-05 | 148 |
| GO:00103891 | Esophagus | ESCC | regulation of G2/M transition of mitotic cell cycle | 64/8552 | 94/18723 | 9.21e-06 | 8.82e-05 | 64 |
| GO:19027491 | Esophagus | ESCC | regulation of cell cycle G2/M phase transition | 68/8552 | 102/18723 | 1.48e-05 | 1.33e-04 | 68 |
| GO:00109721 | Esophagus | ESCC | negative regulation of G2/M transition of mitotic cell cycle | 41/8552 | 60/18723 | 3.25e-04 | 1.91e-03 | 41 |
| GO:19027501 | Esophagus | ESCC | negative regulation of cell cycle G2/M phase transition | 42/8552 | 62/18723 | 3.69e-04 | 2.14e-03 | 42 |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa04630 | Oral cavity | EOLP | JAK-STAT signaling pathway | 35/1218 | 166/8465 | 1.15e-02 | 3.07e-02 | 1.81e-02 | 35 |
| hsa046301 | Oral cavity | EOLP | JAK-STAT signaling pathway | 35/1218 | 166/8465 | 1.15e-02 | 3.07e-02 | 1.81e-02 | 35 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FHL1 | SNV | Missense_Mutation | c.550G>A | p.Asp184Asn | p.D184N | Q13642 | protein_coding | deleterious(0) | possibly_damaging(0.582) | TCGA-A1-A0SE-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FHL1 | SNV | Missense_Mutation | c.769N>T | p.Leu257Phe | p.L257F | Q13642 | protein_coding | deleterious(0) | possibly_damaging(0.771) | TCGA-A8-A092-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | CR | |
| FHL1 | SNV | Missense_Mutation | rs199818971 | c.797N>A | p.Arg266Gln | p.R266Q | Q13642 | protein_coding | deleterious_low_confidence(0.01) | possibly_damaging(0.49) | TCGA-EK-A2RO-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| FHL1 | SNV | Missense_Mutation | novel | c.36N>A | p.Asp12Glu | p.D12E | Q13642 | protein_coding | tolerated(1) | benign(0.047) | TCGA-VS-A953-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| FHL1 | SNV | Missense_Mutation | c.293N>T | p.Ser98Phe | p.S98F | Q13642 | protein_coding | deleterious(0.03) | benign(0.015) | TCGA-VS-A9V0-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD | |
| FHL1 | SNV | Missense_Mutation | novel | c.199C>T | p.Arg67Cys | p.R67C | Q13642 | protein_coding | deleterious(0.01) | probably_damaging(0.969) | TCGA-AA-3950-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FHL1 | SNV | Missense_Mutation | novel | c.796C>T | p.Arg266Trp | p.R266W | Q13642 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.993) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FHL1 | SNV | Missense_Mutation | novel | c.695N>A | p.Arg232Lys | p.R232K | Q13642 | protein_coding | tolerated(0.26) | benign(0) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FHL1 | SNV | Missense_Mutation | novel | c.761N>A | p.Arg254His | p.R254H | Q13642 | protein_coding | deleterious(0.02) | possibly_damaging(0.715) | TCGA-AJ-A3OJ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | carboplatin | CR |
| FHL1 | SNV | Missense_Mutation | rs763012291 | c.467N>T | p.Thr156Ile | p.T156I | Q13642 | protein_coding | deleterious(0.04) | benign(0.038) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |